Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders, 31794-31796 [2024-08811]
Download as PDF
lotter on DSK11XQN23PROD with NOTICES1
31794
Federal Register / Vol. 89, No. 81 / Thursday, April 25, 2024 / Notices
that represent all roadways on the
National Highway System (NHS) and
would have little effect on the Nation’s
pavement condition.
Title: National Tunnel Inspection
Program.
OMB Control: 2125–0640.
Background: This collection is
necessary to meet legislative
requirements of Title 23 United States
Code section 144, and the Code of
Federal Regulations, 23 Highways Part
650, Subpart E—National Tunnel
Inspection Standards which require
States, Federal Agencies, and Tribal
Governments to: (1) perform, and report
inventory and element data from, initial,
routine, damage, in-depth, and special
inspections as appropriate for all
highway tunnels on public roads, and
(2) report critical findings on highway
tunnels. The critical findings
information is periodically provided to
the FHWA. The tunnel information is
used for multiple purposes, including:
(1) the determination of the condition of
the Nation’s tunnels; (2) for various
reports to Congress on Tunnel Safety;
(3) for conducting oversight of the
National Tunnel Inspection Program at
the State, Federal agency, and Tribal
level; and (4) for strategic national
defense needs.
Respondents: 42 States, the District of
Columbia, Puerto Rico and 4 Federal
agencies. The number of inspections per
respondent varies in accordance with
the National Tunnel Inspection
Standards.
Frequency: Annually.
Estimated Average Burden per
Response: The estimated average burden
for each tunnel inspection is 40 hours.
The estimated average burden for
reporting critical findings is 40 hours.
Estimated Total Annual Burden
Hours: The annual burden hours
associated with this renewal is 15,880
hours. This estimated figure is based on
annual instances for tunnel inspections
multiplied by 40 hours (13,960 hours);
plus 40 hours for follow up on critical
findings multiplied by 48 respondents
(1,920 hours) for a combined annual
burden of 15,880 hours.
Public Comments Invited: You are
asked to comment on any aspect of this
information collection, including: (1)
Whether the proposed collection is
necessary for the FHWA’s performance;
(2) the accuracy of the estimated
burdens; (3) ways for the FHWA to
enhance the quality, usefulness, and
clarity of the collected information; and
(4) ways that the burden could be
minimized, including the use of
electronic technology, without reducing
the quality of the collected information.
The agency will summarize and/or
VerDate Sep<11>2014
18:54 Apr 24, 2024
Jkt 262001
include your comments in the request
for OMB’s clearance of this information
collection.
Authority: The Paperwork Reduction
Act of 1995; 44 U.S.C. chapter 35, as
amended; and 49 CFR 1.48.
Issued on: April 22, 2024.
Jazmyne Lewis,
Information Collection Officer.
[FR Doc. 2024–08867 Filed 4–24–24; 8:45 am]
BILLING CODE 4910–22–P
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2013–0106; FMCSA–
2013–0442; FMCSA–2015–0115; FMCSA–
2015–0119; FMCSA–2015–0321; FMCSA–
2017–0181; FMCSA–2017–0254; FMCSA–
2019–0030; FMCSA–2019–0036; FMCSA–
2019–0206; FMCSA–2020–0045; FMCSA–
2020–0046; FMCSA–2021–0026; FMCSA–
2022–0042]
Qualification of Drivers; Exemption
Applications; Epilepsy and Seizure
Disorders
Federal Motor Carrier Safety
Administration (FMCSA), Department
of Transportation (DOT).
ACTION: Notice of renewal of
exemptions; request for comments.
AGENCY:
FMCSA announces its
decision to renew exemptions for 22
individuals from the requirement in the
Federal Motor Carrier Safety
Regulations (FMCSRs) that interstate
commercial motor vehicle (CMV)
drivers have ‘‘no established medical
history or clinical diagnosis of epilepsy
or any other condition which is likely
to cause loss of consciousness or any
loss of ability to control a CMV.’’ The
exemptions enable these individuals
who have had one or more seizures and
are taking anti-seizure medication to
continue to operate CMVs in interstate
commerce.
DATES: Each group of renewed
exemptions are applicable on the dates
stated in the discussions below and will
expire on the dates stated in the
discussions below. Comments must be
received on or before May 28, 2024.
ADDRESSES: You may submit comments
identified by the Federal Docket
Management System Docket No.
FMCSA–2013–0106, Docket No.
FMCSA–2013–0442, Docket No.
FMCSA–2015–0115, Docket No.
FMCSA–2015–0119, Docket No.
FMCSA–2015–0321, Docket No.
FMCSA–2017–0181, Docket No.
FMCSA–2017–0254, Docket No.
FMCSA–2019–0030, Docket No.
SUMMARY:
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
FMCSA–2019–0036, Docket No.
FMCSA–2019–0206, Docket No.
FMCSA–2020–0045, Docket No.
FMCSA–2020–0046, Docket No.
FMCSA–2021–0026, or Docket No.
FMCSA–2022–0042 using any of the
following methods:
• Federal eRulemaking Portal: Go to
www.regulations.gov/, insert the docket
number (FMCSA–2013–0106, FMCSA–
2013–0442, FMCSA–2015–0115,
FMCSA–2015–0119, FMCSA–2015–
0321, FMCSA–2017–0181, FMCSA–
2017–0254, FMCSA–2019–0030,
FMCSA–2019–0036, FMCSA–2019–
0206, FMCSA–2020–0045, FMCSA–
2020–0046, FMCSA–2021–0026, or
FMCSA–2022–0042) in the keyword box
and click ‘‘Search.’’ Next, sort the
results by ‘‘Posted (Newer-Older),’’
choose the first notice listed, and click
on the ‘‘Comment’’ button. Follow the
online instructions for submitting
comments.
• Mail: Dockets Operations; U.S.
Department of Transportation, 1200
New Jersey Avenue SE, West Building
Ground Floor, Washington, DC 20590–
0001.
• Hand Delivery: West Building
Ground Floor, 1200 New Jersey Avenue
SE, Washington, DC 20590–0001
between 9 a.m. and 5 p.m. ET Monday
through Friday, except Federal
Holidays.
• Fax: (202) 493–2251.
To avoid duplication, please use only
one of these four methods. See the
‘‘Public Participation’’ portion of the
SUPPLEMENTARY INFORMATION section for
instructions on submitting comments.
FOR FURTHER INFORMATION CONTACT: Ms.
Christine A. Hydock, Chief, Medical
Programs Division, FMCSA, DOT, 1200
New Jersey Avenue SE, Washington, DC
20590–0001, (202) 366–4001,
fmcsamedical@dot.gov. Office hours are
from 8:30 a.m. to 5 p.m. ET Monday
through Friday, except Federal holidays.
If you have questions regarding viewing
or submitting material to the docket,
contact Dockets Operations, (202) 366–
9826.
SUPPLEMENTARY INFORMATION:
I. Public Participation
A. Submitting Comments
If you submit a comment, please
include the docket number for this
notice (Docket No. FMCSA–2013–0106,
Docket No. FMCSA–2013–0442, Docket
No. FMCSA–2015–0115, Docket No.
FMCSA–2015–0119, Docket No.
FMCSA–2015–0321, Docket No.
FMCSA–2017–0181, Docket No.
FMCSA–2017–0254, Docket No.
FMCSA–2019–0030, Docket No.
FMCSA–2019–0036, Docket No.
E:\FR\FM\25APN1.SGM
25APN1
Federal Register / Vol. 89, No. 81 / Thursday, April 25, 2024 / Notices
lotter on DSK11XQN23PROD with NOTICES1
FMCSA–2019–0206, Docket No.
FMCSA–2020–0045, Docket No.
FMCSA–2020–0046, Docket No.
FMCSA–2021–0026, or Docket No.
FMCSA–2022–0042), indicate the
specific section of this document to
which each comment applies, and
provide a reason for each suggestion or
recommendation. You may submit your
comments and material online or by fax,
mail, or hand delivery, but please use
only one of these means. FMCSA
recommends that you include your
name and a mailing address, an email
address, or a phone number in the body
of your document so that FMCSA can
contact you if there are questions
regarding your submission.
To submit your comment online, go to
www.regulations.gov/, insert the docket
number (FMCSA–2013–0106, FMCSA–
2013–0442, FMCSA–2015–0115,
FMCSA–2015–0119, FMCSA–2015–
0321, FMCSA–2017–0181, FMCSA–
2017–0254, FMCSA–2019–0030,
FMCSA–2019–0036, FMCSA–2019–
0206, FMCSA–2020–0045, FMCSA–
2020–0046, FMCSA–2021–0026, or
FMCSA–2022–0042) in the keyword box
and click ‘‘Search.’’ Next, sort the
results by ‘‘Posted (Newer-Older),’’
choose the first notice listed, click the
‘‘Comment’’ button, and type your
comment into the text box on the
following screen. Choose whether you
are submitting your comment as an
individual or on behalf of a third party
and then submit.
If you submit your comments by mail
or hand delivery, submit them in an
unbound format, no larger than 81⁄2 by
11 inches, suitable for copying and
electronic filing. FMCSA will consider
all comments and material received
during the comment period.
B. Viewing Comments
To view comments go to
www.regulations.gov. Insert the docket
number (FMCSA–2013–0106, FMCSA–
2013–0442, FMCSA–2015–0115,
FMCSA–2015–0119, FMCSA–2015–
0321, FMCSA–2017–0181, FMCSA–
2017–0254, FMCSA–2019–0030,
FMCSA–2019–0036, FMCSA–2019–
0206, FMCSA–2020–0045, FMCSA–
2020–0046, FMCSA–2021–0026, or
FMCSA–2022–0042) in the keyword box
and click ‘‘Search.’’ Next, sort the
results by ‘‘Posted (Newer-Older),’’
choose the first notice listed, and click
‘‘Browse Comments.’’ If you do not have
access to the internet, you may view the
docket online by visiting Dockets
Operations on the ground floor of the
DOT West Building, 1200 New Jersey
Avenue SE, Washington, DC 20590–
0001, between 9 a.m. and 5 p.m. ET
Monday through Friday, except Federal
VerDate Sep<11>2014
18:54 Apr 24, 2024
Jkt 262001
holidays. To be sure someone is there to
help you, please call (202) 366–9317 or
(202) 366–9826 before visiting Dockets
Operations.
C. Privacy Act
In accordance with 49 U.S.C.
31315(b)(6), DOT solicits comments
from the public on the exemption
request. DOT posts these comments,
without edit, including any personal
information the commenter provides, to
www.regulations.gov. As described in
the system of records notice DOT/ALL
14 (Federal Docket Management
System), which can be reviewed at
https://www.transportation.gov/
individuals/privacy/privacy-act-systemrecords-notices, the comments are
searchable by the name of the submitter.
II. Background
Under 49 U.S.C. 31136(e) and
31315(b), FMCSA may grant an
exemption from the FMCSRs for no
longer than a 5-year period if it finds
such exemption would likely achieve a
level of safety that is equivalent to, or
greater than, the level that would be
achieved absent such exemption. The
statutes also allow the Agency to renew
exemptions at the end of the 5-year
period. However, FMCSA grants
medical exemptions from the FMCSRs
for a 2-year period to align with the
maximum duration of a driver’s medical
certification.
The physical qualification standard
for drivers regarding epilepsy found in
49 CFR 391.41(b)(8) states that a person
is physically qualified to drive a CMV
if that person has no established
medical history or clinical diagnosis of
epilepsy or any other condition which
is likely to cause the loss of
consciousness or any loss of ability to
control a CMV.
In addition to the regulations, FMCSA
has published advisory criteria 1 to
assist Medical Examiners in
determining whether drivers with
certain medical conditions are qualified
to operate a CMV in interstate
commerce.
The 22 individuals listed in this
notice have requested renewal of their
exemptions from the epilepsy and
seizure disorders prohibition in
§ 391.41(b)(8), in accordance with
FMCSA procedures. Accordingly,
FMCSA has evaluated these
applications for renewal on their merits
1 These criteria may be found in APPENDIX A TO
PART 391—MEDICAL ADVISORY CRITERIA,
section H. Epilepsy: § 391.41(b)(8), paragraphs 3, 4,
and 5, which is available on the internet at https://
www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/
CFR-2015-title49-vol5-part391-appA.pdf.
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
31795
and decided to extend each exemption
for a renewable 2-year period.
III. Request for Comments
Interested parties or organizations
possessing information that would
otherwise show that any, or all, of these
drivers are not currently achieving the
statutory level of safety should
immediately notify FMCSA. The
Agency will evaluate any adverse
evidence submitted and, if safety is
being compromised or if continuation of
the exemption would not be consistent
with the goals and objectives of 49
U.S.C. 31136(e) and 31315(b), FMCSA
will take immediate steps to revoke the
exemption of a driver.
IV. Basis for Renewing Exemptions
In accordance with 49 U.S.C. 31136(e)
and 31315(b), each of the 22 applicants
has satisfied the renewal conditions for
obtaining an exemption from the
epilepsy and seizure disorders
prohibition. The 22 drivers in this
notice remain in good standing with the
Agency, have maintained their medical
monitoring and have not exhibited any
medical issues that would compromise
their ability to safely operate a CMV
during the previous 2-year exemption
period. In addition, for commercial
driver’s license (CDL) holders, the
Commercial Driver’s License
Information System and the Motor
Carrier Management Information System
are searched for crash and violation
data. For non-CDL holders, the Agency
reviews the driving records from the
State Driver’s Licensing Agency. These
factors provide an adequate basis for
predicting each driver’s ability to
continue to safely operate a CMV in
interstate commerce. Therefore, FMCSA
concludes that extending the exemption
for each renewal applicant for a period
of 2 years is likely to achieve a level of
safety equal to that existing without the
exemption.
In accordance with 49 U.S.C. 31136(e)
and 31315(b), the following groups of
drivers received renewed exemptions in
the month of May and are discussed
below.
As of May 6, 2024, and in accordance
with 49 U.S.C. 31136(e) and 31315(b),
the following nine individuals have
satisfied the renewal conditions for
obtaining an exemption from the
epilepsy and seizure disorders
prohibition in the FMCSRs for interstate
CMV drivers:
Gary Clark (KY)
Michael Curtis (DE)
Callon Hegman (IL)
Zachary Henson (IL)
Gregory Johnson (NC)
Robert Lombardo (CA)
E:\FR\FM\25APN1.SGM
25APN1
31796
Federal Register / Vol. 89, No. 81 / Thursday, April 25, 2024 / Notices
Armando Macias-Tovar (FL)
Joseph Mendoza (IN)
Douglas Slagel (OH)
The drivers were included in docket
number FMCSA–2013–0106, FMCSA–
2017–0181, FMCSA–2021–0026, or
FMCSA–2022–0042 Their exemptions
are applicable as of May 6, 2024 and
will expire on May 6, 2026.
As of May 15, 2024, and in
accordance with 49 U.S.C. 31136(e) and
31315(b), the following 13 individuals
have satisfied the renewal conditions for
obtaining an exemption from the
epilepsy and seizure disorders
prohibition in the FMCSRs for interstate
CMV drivers:
Barry Dull (OH)
Robert J. Forney (WI)
Matthew Heinen (MN)
Logan Hertzler (PA)
Preston Kanagy (TN)
Kenneth Lewis (NC)
Kevin Market (OH)
Gary Olsen (MN)
Randy Pinto (PA)
Jeffrey Totten (KS)
Paul Vitous (WA)
Thomas Vivirito (PA)
Robert J. Wenner (MN)
The drivers were included in docket
number FMCSA–2013–0442, FMCSA–
2015–0115, FMCSA–2015–0119,
FMCSA–2015–0321, FMCSA–2017–
0181, FMCSA–2017–0254, FMCSA–
2019–0030, FMCSA–2019–0036,
FMCSA–2020–0045, or FMCSA–2020–
0046. Their exemptions are applicable
as of May 15, 2024 and will expire on
May 15, 2026.
lotter on DSK11XQN23PROD with NOTICES1
V. Conditions and Requirements
The exemptions are extended subject
to the following conditions: (1) each
driver must remain seizure-free and
maintain a stable treatment during the
2-year exemption period; (2) each driver
must submit annual reports from their
treating physicians attesting to the
stability of treatment and that the driver
has remained seizure-free; (3) each
driver must undergo an annual medical
examination by a certified ME, as
defined by § 390.5; and (4) each driver
must provide a copy of the annual
medical certification to the employer for
retention in the driver’s qualification
file, or keep a copy of his/her driver’s
qualification file if he/she is selfemployed. The driver must also have a
copy of the exemption when driving, for
presentation to a duly authorized
Federal, State, or local enforcement
official. The exemption will be
rescinded if: (1) the person fails to
comply with the terms and conditions
of the exemption; (2) the exemption has
resulted in a lower level of safety than
VerDate Sep<11>2014
18:54 Apr 24, 2024
Jkt 262001
was maintained before it was granted; or
(3) continuation of the exemption would
not be consistent with the goals and
objectives of 49 U.S.C. 31136(e) and
31315(b).
VI. Preemption
During the period the exemption is in
effect, no State shall enforce any law or
regulation that conflicts with this
exemption with respect to a person
operating under the exemption.
VII. Conclusion
Based on its evaluation of the 22
exemption applications, FMCSA renews
the exemptions of the aforementioned
drivers from the epilepsy and seizure
disorders prohibition in § 391.41(b)(8).
In accordance with 49 U.S.C. 31136(e)
and 31315(b), each exemption will be
valid for 2 years unless revoked earlier
by FMCSA.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2024–08811 Filed 4–24–24; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Federal Transit Administration
[Docket No.: FTA–2023–0006]
Notice of Availability of Programmatic
Assessment of Greenhouse Gas
Emissions From Transit Projects
Federal Transit Administration
(FTA), Department of Transportation
(DOT).
ACTION: Notice of availability.
AGENCY:
The Federal Transit
Administration (FTA) announces the
availability of a Programmatic
Assessment of Greenhouse Gas
Emissions from Transit Projects
(Programmatic Assessment). On
September 25, 2023, FTA announced in
the Federal Register the availability of
the draft Programmatic Assessment and
requested public comment. FTA
received six comment letters and
presents its responses to those
comments in this notice.
DATES: The final Programmatic
Assessment is effective immediately.
ADDRESSES: The final Programmatic
Assessment will be made available in
the U.S. Government’s electronic docket
site at https://www.regulations.gov/
docket/FTA-2023-0006 and on the FTA
website at https://www.transit.dot.gov/
regulations-and-programs/
environmental-programs/climateconsiderations.
SUMMARY:
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Megan Blum, Office of Environmental
Programs, (202) 366–0463,
Megan.Blum@dot.gov, or Alexandra
Brun, Office of Environmental
Programs, (202) 366–7469,
Alexandra.Brun@dot.gov; Mark
Montgomery, Office of Chief Counsel,
(202) 366–1017, Mark.Montgomery@
dot.gov. Office hours are from 9:00 a.m.
to 5:00 p.m. ET, Monday through
Friday, except Federal holidays.
SUPPLEMENTARY INFORMATION:
Background
The National Environmental Policy
Act (NEPA) requires Federal agencies to
disclose and analyze the environmental
effects of their proposed actions. In
2016, the Council on Environmental
Quality (CEQ) issued the Final
Guidance for Federal Departments and
Agencies on Consideration of
Greenhouse Gas Emissions and the
Effects of Climate Change in National
Environmental Policy Act Reviews (81
FR 51866) (2016 CEQ guidance), which
provided a framework for agencies to
consider the effects of a proposed action
on climate change, as indicated by its
estimated GHG emissions and advised
agencies to assess the effects of climate
change on their proposed actions. The
2016 CEQ guidance also acknowledged
that incorporation by reference is of
great value in considering GHG
emissions or the implications of climate
change for the proposed action and its
environmental effects. The 2016 CEQ
guidance noted that an agency may
decide that it would be useful and
efficient to provide an aggregate analysis
of GHG emissions or climate change
effects in a programmatic analysis and
then incorporate that analysis by
reference into future NEPA reviews.
FTA considers it practicable to assess
the effects of GHG emissions and
climate change for transit projects at a
programmatic level, where possible.
In January 2017, FTA published a
Programmatic Assessment of
Greenhouse Gas Emissions from Transit
Projects (82 FR 5636) based on the 2016
CEQ guidance framework. In January
2023, CEQ issued the National
Environmental Policy Act Guidance on
Consideration of Greenhouse Gas
Emissions and Climate Change (88 FR
1196) (2023 CEQ guidance) to assist
agencies in analyzing greenhouse gas
(GHG) emissions and climate change
effects of their proposed actions under
NEPA. The 2023 CEQ guidance
continues to support a programmatic
approach for assessing GHG emissions
from transit projects.
The 2024 Programmatic Assessment
of Greenhouse Gas Emissions from
E:\FR\FM\25APN1.SGM
25APN1
Agencies
[Federal Register Volume 89, Number 81 (Thursday, April 25, 2024)]
[Notices]
[Pages 31794-31796]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-08811]
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2013-0106; FMCSA-2013-0442; FMCSA-2015-0115; FMCSA-
2015-0119; FMCSA-2015-0321; FMCSA-2017-0181; FMCSA-2017-0254; FMCSA-
2019-0030; FMCSA-2019-0036; FMCSA-2019-0206; FMCSA-2020-0045; FMCSA-
2020-0046; FMCSA-2021-0026; FMCSA-2022-0042]
Qualification of Drivers; Exemption Applications; Epilepsy and
Seizure Disorders
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), Department
of Transportation (DOT).
ACTION: Notice of renewal of exemptions; request for comments.
-----------------------------------------------------------------------
SUMMARY: FMCSA announces its decision to renew exemptions for 22
individuals from the requirement in the Federal Motor Carrier Safety
Regulations (FMCSRs) that interstate commercial motor vehicle (CMV)
drivers have ``no established medical history or clinical diagnosis of
epilepsy or any other condition which is likely to cause loss of
consciousness or any loss of ability to control a CMV.'' The exemptions
enable these individuals who have had one or more seizures and are
taking anti-seizure medication to continue to operate CMVs in
interstate commerce.
DATES: Each group of renewed exemptions are applicable on the dates
stated in the discussions below and will expire on the dates stated in
the discussions below. Comments must be received on or before May 28,
2024.
ADDRESSES: You may submit comments identified by the Federal Docket
Management System Docket No. FMCSA-2013-0106, Docket No. FMCSA-2013-
0442, Docket No. FMCSA-2015-0115, Docket No. FMCSA-2015-0119, Docket
No. FMCSA-2015-0321, Docket No. FMCSA-2017-0181, Docket No. FMCSA-2017-
0254, Docket No. FMCSA-2019-0030, Docket No. FMCSA-2019-0036, Docket
No. FMCSA-2019-0206, Docket No. FMCSA-2020-0045, Docket No. FMCSA-2020-
0046, Docket No. FMCSA-2021-0026, or Docket No. FMCSA-2022-0042 using
any of the following methods:
Federal eRulemaking Portal: Go to www.regulations.gov/,
insert the docket number (FMCSA-2013-0106, FMCSA-2013-0442, FMCSA-2015-
0115, FMCSA-2015-0119, FMCSA-2015-0321, FMCSA-2017-0181, FMCSA-2017-
0254, FMCSA-2019-0030, FMCSA-2019-0036, FMCSA-2019-0206, FMCSA-2020-
0045, FMCSA-2020-0046, FMCSA-2021-0026, or FMCSA-2022-0042) in the
keyword box and click ``Search.'' Next, sort the results by ``Posted
(Newer-Older),'' choose the first notice listed, and click on the
``Comment'' button. Follow the online instructions for submitting
comments.
Mail: Dockets Operations; U.S. Department of
Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor,
Washington, DC 20590-0001.
Hand Delivery: West Building Ground Floor, 1200 New Jersey
Avenue SE, Washington, DC 20590-0001 between 9 a.m. and 5 p.m. ET
Monday through Friday, except Federal Holidays.
Fax: (202) 493-2251.
To avoid duplication, please use only one of these four methods.
See the ``Public Participation'' portion of the SUPPLEMENTARY
INFORMATION section for instructions on submitting comments.
FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division, FMCSA, DOT, 1200 New Jersey Avenue SE,
Washington, DC 20590-0001, (202) 366-4001, [email protected]. Office
hours are from 8:30 a.m. to 5 p.m. ET Monday through Friday, except
Federal holidays. If you have questions regarding viewing or submitting
material to the docket, contact Dockets Operations, (202) 366-9826.
SUPPLEMENTARY INFORMATION:
I. Public Participation
A. Submitting Comments
If you submit a comment, please include the docket number for this
notice (Docket No. FMCSA-2013-0106, Docket No. FMCSA-2013-0442, Docket
No. FMCSA-2015-0115, Docket No. FMCSA-2015-0119, Docket No. FMCSA-2015-
0321, Docket No. FMCSA-2017-0181, Docket No. FMCSA-2017-0254, Docket
No. FMCSA-2019-0030, Docket No. FMCSA-2019-0036, Docket No.
[[Page 31795]]
FMCSA-2019-0206, Docket No. FMCSA-2020-0045, Docket No. FMCSA-2020-
0046, Docket No. FMCSA-2021-0026, or Docket No. FMCSA-2022-0042),
indicate the specific section of this document to which each comment
applies, and provide a reason for each suggestion or recommendation.
You may submit your comments and material online or by fax, mail, or
hand delivery, but please use only one of these means. FMCSA recommends
that you include your name and a mailing address, an email address, or
a phone number in the body of your document so that FMCSA can contact
you if there are questions regarding your submission.
To submit your comment online, go to www.regulations.gov/, insert
the docket number (FMCSA-2013-0106, FMCSA-2013-0442, FMCSA-2015-0115,
FMCSA-2015-0119, FMCSA-2015-0321, FMCSA-2017-0181, FMCSA-2017-0254,
FMCSA-2019-0030, FMCSA-2019-0036, FMCSA-2019-0206, FMCSA-2020-0045,
FMCSA-2020-0046, FMCSA-2021-0026, or FMCSA-2022-0042) in the keyword
box and click ``Search.'' Next, sort the results by ``Posted (Newer-
Older),'' choose the first notice listed, click the ``Comment'' button,
and type your comment into the text box on the following screen. Choose
whether you are submitting your comment as an individual or on behalf
of a third party and then submit.
If you submit your comments by mail or hand delivery, submit them
in an unbound format, no larger than 8\1/2\ by 11 inches, suitable for
copying and electronic filing. FMCSA will consider all comments and
material received during the comment period.
B. Viewing Comments
To view comments go to www.regulations.gov. Insert the docket
number (FMCSA-2013-0106, FMCSA-2013-0442, FMCSA-2015-0115, FMCSA-2015-
0119, FMCSA-2015-0321, FMCSA-2017-0181, FMCSA-2017-0254, FMCSA-2019-
0030, FMCSA-2019-0036, FMCSA-2019-0206, FMCSA-2020-0045, FMCSA-2020-
0046, FMCSA-2021-0026, or FMCSA-2022-0042) in the keyword box and click
``Search.'' Next, sort the results by ``Posted (Newer-Older),'' choose
the first notice listed, and click ``Browse Comments.'' If you do not
have access to the internet, you may view the docket online by visiting
Dockets Operations on the ground floor of the DOT West Building, 1200
New Jersey Avenue SE, Washington, DC 20590-0001, between 9 a.m. and 5
p.m. ET Monday through Friday, except Federal holidays. To be sure
someone is there to help you, please call (202) 366-9317 or (202) 366-
9826 before visiting Dockets Operations.
C. Privacy Act
In accordance with 49 U.S.C. 31315(b)(6), DOT solicits comments
from the public on the exemption request. DOT posts these comments,
without edit, including any personal information the commenter
provides, to www.regulations.gov. As described in the system of records
notice DOT/ALL 14 (Federal Docket Management System), which can be
reviewed at https://www.transportation.gov/individuals/privacy/privacy-act-system-records-notices, the comments are searchable by the name of
the submitter.
II. Background
Under 49 U.S.C. 31136(e) and 31315(b), FMCSA may grant an exemption
from the FMCSRs for no longer than a 5-year period if it finds such
exemption would likely achieve a level of safety that is equivalent to,
or greater than, the level that would be achieved absent such
exemption. The statutes also allow the Agency to renew exemptions at
the end of the 5-year period. However, FMCSA grants medical exemptions
from the FMCSRs for a 2-year period to align with the maximum duration
of a driver's medical certification.
The physical qualification standard for drivers regarding epilepsy
found in 49 CFR 391.41(b)(8) states that a person is physically
qualified to drive a CMV if that person has no established medical
history or clinical diagnosis of epilepsy or any other condition which
is likely to cause the loss of consciousness or any loss of ability to
control a CMV.
In addition to the regulations, FMCSA has published advisory
criteria \1\ to assist Medical Examiners in determining whether drivers
with certain medical conditions are qualified to operate a CMV in
interstate commerce.
---------------------------------------------------------------------------
\1\ These criteria may be found in APPENDIX A TO PART 391--
MEDICAL ADVISORY CRITERIA, section H. Epilepsy: Sec. 391.41(b)(8),
paragraphs 3, 4, and 5, which is available on the internet at
https://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/CFR-2015-title49-vol5-part391-appA.pdf.
---------------------------------------------------------------------------
The 22 individuals listed in this notice have requested renewal of
their exemptions from the epilepsy and seizure disorders prohibition in
Sec. 391.41(b)(8), in accordance with FMCSA procedures. Accordingly,
FMCSA has evaluated these applications for renewal on their merits and
decided to extend each exemption for a renewable 2-year period.
III. Request for Comments
Interested parties or organizations possessing information that
would otherwise show that any, or all, of these drivers are not
currently achieving the statutory level of safety should immediately
notify FMCSA. The Agency will evaluate any adverse evidence submitted
and, if safety is being compromised or if continuation of the exemption
would not be consistent with the goals and objectives of 49 U.S.C.
31136(e) and 31315(b), FMCSA will take immediate steps to revoke the
exemption of a driver.
IV. Basis for Renewing Exemptions
In accordance with 49 U.S.C. 31136(e) and 31315(b), each of the 22
applicants has satisfied the renewal conditions for obtaining an
exemption from the epilepsy and seizure disorders prohibition. The 22
drivers in this notice remain in good standing with the Agency, have
maintained their medical monitoring and have not exhibited any medical
issues that would compromise their ability to safely operate a CMV
during the previous 2-year exemption period. In addition, for
commercial driver's license (CDL) holders, the Commercial Driver's
License Information System and the Motor Carrier Management Information
System are searched for crash and violation data. For non-CDL holders,
the Agency reviews the driving records from the State Driver's
Licensing Agency. These factors provide an adequate basis for
predicting each driver's ability to continue to safely operate a CMV in
interstate commerce. Therefore, FMCSA concludes that extending the
exemption for each renewal applicant for a period of 2 years is likely
to achieve a level of safety equal to that existing without the
exemption.
In accordance with 49 U.S.C. 31136(e) and 31315(b), the following
groups of drivers received renewed exemptions in the month of May and
are discussed below.
As of May 6, 2024, and in accordance with 49 U.S.C. 31136(e) and
31315(b), the following nine individuals have satisfied the renewal
conditions for obtaining an exemption from the epilepsy and seizure
disorders prohibition in the FMCSRs for interstate CMV drivers:
Gary Clark (KY)
Michael Curtis (DE)
Callon Hegman (IL)
Zachary Henson (IL)
Gregory Johnson (NC)
Robert Lombardo (CA)
[[Page 31796]]
Armando Macias-Tovar (FL)
Joseph Mendoza (IN)
Douglas Slagel (OH)
The drivers were included in docket number FMCSA-2013-0106, FMCSA-
2017-0181, FMCSA-2021-0026, or FMCSA-2022-0042 Their exemptions are
applicable as of May 6, 2024 and will expire on May 6, 2026.
As of May 15, 2024, and in accordance with 49 U.S.C. 31136(e) and
31315(b), the following 13 individuals have satisfied the renewal
conditions for obtaining an exemption from the epilepsy and seizure
disorders prohibition in the FMCSRs for interstate CMV drivers:
Barry Dull (OH)
Robert J. Forney (WI)
Matthew Heinen (MN)
Logan Hertzler (PA)
Preston Kanagy (TN)
Kenneth Lewis (NC)
Kevin Market (OH)
Gary Olsen (MN)
Randy Pinto (PA)
Jeffrey Totten (KS)
Paul Vitous (WA)
Thomas Vivirito (PA)
Robert J. Wenner (MN)
The drivers were included in docket number FMCSA-2013-0442, FMCSA-
2015-0115, FMCSA-2015-0119, FMCSA-2015-0321, FMCSA-2017-0181, FMCSA-
2017-0254, FMCSA-2019-0030, FMCSA-2019-0036, FMCSA-2020-0045, or FMCSA-
2020-0046. Their exemptions are applicable as of May 15, 2024 and will
expire on May 15, 2026.
V. Conditions and Requirements
The exemptions are extended subject to the following conditions:
(1) each driver must remain seizure-free and maintain a stable
treatment during the 2-year exemption period; (2) each driver must
submit annual reports from their treating physicians attesting to the
stability of treatment and that the driver has remained seizure-free;
(3) each driver must undergo an annual medical examination by a
certified ME, as defined by Sec. 390.5; and (4) each driver must
provide a copy of the annual medical certification to the employer for
retention in the driver's qualification file, or keep a copy of his/her
driver's qualification file if he/she is self-employed. The driver must
also have a copy of the exemption when driving, for presentation to a
duly authorized Federal, State, or local enforcement official. The
exemption will be rescinded if: (1) the person fails to comply with the
terms and conditions of the exemption; (2) the exemption has resulted
in a lower level of safety than was maintained before it was granted;
or (3) continuation of the exemption would not be consistent with the
goals and objectives of 49 U.S.C. 31136(e) and 31315(b).
VI. Preemption
During the period the exemption is in effect, no State shall
enforce any law or regulation that conflicts with this exemption with
respect to a person operating under the exemption.
VII. Conclusion
Based on its evaluation of the 22 exemption applications, FMCSA
renews the exemptions of the aforementioned drivers from the epilepsy
and seizure disorders prohibition in Sec. 391.41(b)(8). In accordance
with 49 U.S.C. 31136(e) and 31315(b), each exemption will be valid for
2 years unless revoked earlier by FMCSA.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2024-08811 Filed 4-24-24; 8:45 am]
BILLING CODE 4910-EX-P